180 related articles for article (PubMed ID: 30415890)
1. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.
Chen X; Umeh CC; Tainsh RE; Feng DD; Maguire M; Zuo F; Rahimian M; Logan R; Wang X; Ascherio A; Macklin EA; Buys ES; Schwarzschild MA;
EBioMedicine; 2018 Nov; 37():259-268. PubMed ID: 30415890
[TBL] [Abstract][Full Text] [Related]
2. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide variant by serum urate interaction in Parkinson's disease.
Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
[TBL] [Abstract][Full Text] [Related]
4. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
Schwarzschild MA; Macklin EA; Bakshi R; Battacharyya S; Logan R; Espay AJ; Hung AY; Bwala G; Goetz CG; Russell DS; Goudreau JL; Parashos SA; Saint-Hilaire MH; Rudolph A; Hare JM; Curhan GC; Ascherio A;
Neurology; 2019 Oct; 93(14):e1328-e1338. PubMed ID: 31484712
[TBL] [Abstract][Full Text] [Related]
5. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
; Schwarzschild MA; Ascherio A; Beal MF; Cudkowicz ME; Curhan GC; Hare JM; Hooper DC; Kieburtz KD; Macklin EA; Oakes D; Rudolph A; Shoulson I; Tennis MK; Espay AJ; Gartner M; Hung A; Bwala G; Lenehan R; Encarnacion E; Ainslie M; Castillo R; Togasaki D; Barles G; Friedman JH; Niles L; Carter JH; Murray M; Goetz CG; Jaglin J; Ahmed A; Russell DS; Cotto C; Goudreau JL; Russell D; Parashos SA; Ede P; Saint-Hilaire MH; Thomas CA; James R; Stacy MA; Johnson J; Gauger L; Antonelle de Marcaida J; Thurlow S; Isaacson SH; Carvajal L; Rao J; Cook M; Hope-Porche C; McClurg L; Grasso DL; Logan R; Orme C; Ross T; Brocht AF; Constantinescu R; Sharma S; Venuto C; Weber J; Eaton K
JAMA Neurol; 2014 Feb; 71(2):141-50. PubMed ID: 24366103
[TBL] [Abstract][Full Text] [Related]
6. A stable liver-specific urate oxidase gene knockout hyperuricemia mouse model finds activated hepatic de novo purine biosynthesis and urate nephropathy.
Pang L; Liang N; Li C; Merriman TR; Zhang H; Yan F; Sun W; Li R; Xue X; Liu Z; Wang C; Cheng X; Chen S; Yin H; Dalbeth N; Yuan X
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167009. PubMed ID: 38237409
[TBL] [Abstract][Full Text] [Related]
7. One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
Iwaki H; Ando R; Miyaue N; Tada S; Tsujii T; Yabe H; Nishikawa N; Nagai M; Nomoto M
J Neurol Sci; 2017 Dec; 383():75-78. PubMed ID: 29246629
[TBL] [Abstract][Full Text] [Related]
8. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.
Chen X; Burdett TC; Desjardins CA; Logan R; Cipriani S; Xu Y; Schwarzschild MA
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):300-5. PubMed ID: 23248282
[TBL] [Abstract][Full Text] [Related]
9. Does Serum Urate Change as Parkinson's Disease Progresses?
Hasimoglu YG; Chen X; Bakshi R; Schwarzschild MA; Macklin EA
J Parkinsons Dis; 2020; 10(4):1571-1576. PubMed ID: 32773396
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants related to urate and risk of Parkinson's disease.
Hughes KC; Gao X; O'Reilly EJ; Kim IY; Wang M; Weisskopf MG; Schwarzschild MA; Ascherio A
Parkinsonism Relat Disord; 2018 Aug; 53():4-9. PubMed ID: 29789205
[TBL] [Abstract][Full Text] [Related]
11. Urate as a predictor of the rate of clinical decline in Parkinson disease.
Ascherio A; LeWitt PA; Xu K; Eberly S; Watts A; Matson WR; Marras C; Kieburtz K; Rudolph A; Bogdanov MB; Schwid SR; Tennis M; Tanner CM; Beal MF; Lang AE; Oakes D; Fahn S; Shoulson I; Schwarzschild MA;
Arch Neurol; 2009 Dec; 66(12):1460-8. PubMed ID: 19822770
[TBL] [Abstract][Full Text] [Related]
12. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Lu J; Hou X; Yuan X; Cui L; Liu Z; Li X; Ma L; Cheng X; Xin Y; Wang C; Zhang K; Wang X; Ren W; Sun R; Jia Z; Tian Z; Mi QS; Li C
Kidney Int; 2018 Jan; 93(1):69-80. PubMed ID: 28729031
[TBL] [Abstract][Full Text] [Related]
13. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
Bhattacharyya S; Bakshi R; Logan R; Ascherio A; Macklin EA; Schwarzschild MA
Mov Disord; 2016 Mar; 31(3):417-21. PubMed ID: 26805433
[TBL] [Abstract][Full Text] [Related]
14. Urate as a marker of development and progression in Parkinson's disease.
Constantinescu R; Zetterberg H
Drugs Today (Barc); 2011 May; 47(5):369-80. PubMed ID: 22013567
[TBL] [Abstract][Full Text] [Related]
15. Plasma urate and risk of Parkinson's disease.
Weisskopf MG; O'Reilly E; Chen H; Schwarzschild MA; Ascherio A
Am J Epidemiol; 2007 Sep; 166(5):561-7. PubMed ID: 17584757
[TBL] [Abstract][Full Text] [Related]
16. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
17. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA
Ann Neurol; 2019 Apr; 85(4):593-599. PubMed ID: 30761591
[TBL] [Abstract][Full Text] [Related]
18. Plasma urate and risk of Parkinson's disease: A mendelian randomization study.
Kobylecki CJ; Nordestgaard BG; Afzal S
Ann Neurol; 2018 Aug; 84(2):178-190. PubMed ID: 30014508
[TBL] [Abstract][Full Text] [Related]
19. Serum urate and the risk of Parkinson's disease: results from a meta-analysis.
Shen C; Guo Y; Luo W; Lin C; Ding M
Can J Neurol Sci; 2013 Jan; 40(1):73-9. PubMed ID: 23250131
[TBL] [Abstract][Full Text] [Related]
20. Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis.
Lu J; Sun M; Wu X; Yuan X; Liu Z; Qu X; Ji X; Merriman TR; Li C
FEBS J; 2019 Apr; 286(7):1346-1359. PubMed ID: 30690853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
